Scholars Central

Conference abstractPublished 29 Oct 2012

Identification of selective PTP1B allosteric inhibitors using in silico approaches

Authors: M. Elizabeth Sobhia, Ranajit Shinde

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Proteins may be characterized by the presence of numerous binding sites. Active sites are the key sites of proteins, generally located in cavities that are rich in functional groups and small molecules are often attracted to these cavities for binding. Allosteric sites are specific sites present on the surface of enzymes or protein molecules to which the modulator or effector molecule bind and subsequently modify the protein activity by either activating it or inhibiting it. The use of allosteric sites as potential drug targets has gained importance ever since their discovery by means of X-ray crystallography. Protein tyrosine phosphatase 1B (PTP1B) has been identified as an attractive target for both type 2 diabetes and obesity. It has been shown to play a negative role in the insulin signaling pathways. The known active site PTP1B inhibitors lack appropriate pharmacokinetic properties and selectivity over other PTPs. In the present study we have used different in silico approaches for the design of selective and novel PTP1B allosteric inhibitors. A shape based virtual screening protocol was employed to identify potential PTP1B allosteric inhibitors. Some of the molecules have shown high percentage of inhibition in enzymatic assays. Using molecular dynamics approaches, we have also studied the flexibility of the alpha-7 helix in PTP1B and have carried out binding free energy calculations and energy decomposition analysis for the allosteric inhibitors. We have also characterized the different geometric criteria required for studying the open and closed state of WPD loops in PTP1B. The results will be discussed in the presentation.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Drug Designing: Open Access.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalDrug Designing: Open Access
  • SubjectPharmaceutical Sciences
  • BylineArticles whose byline prints “M. Elizabeth Sobhia”
  • BylineArticles whose byline prints “Ranajit Shinde”